Co-development Deals in Pharmaceuticals and Biotechnology 2016-2024
Co-development Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2024
Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals.
Fully revised and updated, the report provides details of co-development deals from 2016 to 2024.
The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of co-development dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of co-development deals.
Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.
The deal directory includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.
Key benefits
Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse co-development deals
- Benchmark analysis – identify market value of transactions
- Financials terms
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
Co-development Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading biopharma companies worldwide.
Co-development Deals in Pharmaceuticals and Biotechnology includes:
- Trends in co-development dealmaking in the biopharma industry
- Overview of co-development deal structure
- Directory of co-development deal records covering pharmaceutical and biotechnology
- The leading co-development deals by value
- Most active co-development dealmakers
- The leading co-development partnering resources
In Co-development Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Co-development Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for co-development deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse co-development deals
- Benchmark analysis – identify market value of transactions
- Financials terms
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in co-development dealmaking
2.1. Introduction
2.2. Definition of co-development deal
2.3. Trends in co-development deals since 2016
2.3.1. Co-development dealmaking by year, 2016-2024
2.3.2. Co-development dealmaking by phase of development, 2016-2024
2.3.3. Co-development dealmaking by industry sector, 2016-2024
2.3.4. Co-development dealmaking by therapy area, 2016-2024
2.3.5. Co-development dealmaking by technology type, 2016-2024
2.3.6. Co-development dealmaking by most active company, 2016-2024
2.4. Reasons for entering into co-development partnering deals
2.5. The future of co-development deals
Chapter 3 – Overview of co-development deal structure
3.1. Introduction
3.2. Co-development agreement structure
Chapter 4 – Leading co-development deals
4.1. Introduction
4.2. Top co-development deals by value
Chapter 5 – Top 25 most active co-development dealmakers
5.1. Introduction
5.2. Top 25 most active co-development dealmakers
Chapter 6 – Co-development deals including contracts directory
6.1. Introduction
6.2. Co-development deals with contracts 2016-2024
Deal directory
Deal directory – co-development dealmaking by companies A-Z
Deal directory – co-development dealmaking by therapy area
Deal directory – co-development dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of co-development deal
Figure 2: Trends in co-development deal announcements, 2016-2024
Figure 3: Co-development deals signed at each phase of development, 2016-2024
Figure 4: Co-development deals by industry sector, 2016-2024
Figure 5: Co-development deals by therapy area, 2016-2024
Figure 6: Co-development deals by technology type, 2016-2024
Figure 7: Top 25 most active co-development dealmakers, 2016-2024
Figure 8: Top co-development deals by value, 2016-2024
Figure 9: Most active co-development dealmakers, 2016-2024
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
